- Home
- MU vs GILD Comparison
MU vs GILD Comparison
Compare MU & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MU
- GILD
- Stock Information
- Founded
- MU 1978
- GILD 1987
- Country
- MU United States
- GILD United States
- Employees
- MU N/A
- GILD 17600
- Industry
- MU Semiconductors
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MU Technology
- GILD Health Care
- Exchange
- MU Nasdaq
- GILD Nasdaq
- Market Cap
- MU 135.3B
- GILD 144.1B
- IPO Year
- MU N/A
- GILD 1992
- Fundamental
- Price
- MU $117.68
- GILD $114.77
- Analyst Decision
- MU Strong Buy
- GILD Buy
- Analyst Count
- MU 28
- GILD 23
- Target Price
- MU $152.75
- GILD $115.68
- AVG Volume (30 Days)
- MU 19.1M
- GILD 6.6M
- Earning Date
- MU 09-24-2025
- GILD 08-07-2025
- Dividend Yield
- MU 0.39%
- GILD 2.75%
- EPS Growth
- MU N/A
- GILD 496.80
- EPS
- MU 5.50
- GILD 5.01
- Revenue
- MU $33,813,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- MU $50.65
- GILD $1.91
- Revenue Next Year
- MU $30.83
- GILD $3.75
- P/E Ratio
- MU $21.40
- GILD $22.90
- Revenue Growth
- MU 58.22
- GILD 3.81
- 52 Week Low
- MU $61.54
- GILD $75.35
- 52 Week High
- MU $129.85
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- MU 50.60
- GILD 48.81
- Support Level
- MU $113.46
- GILD $117.07
- Resistance Level
- MU $124.24
- GILD $120.89
- Average True Range (ATR)
- MU 4.32
- GILD 2.62
- MACD
- MU -0.09
- GILD -0.31
- Stochastic Oscillator
- MU 50.02
- GILD 46.88
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).